$PHAT
Phathom Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022013743 Filed on August 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $23.51M $26.55M $20.25M
YoY Change 42.23% 93.47% 55.74%
% of Gross Profit
Research & Development $19.02M $18.82M $17.66M
YoY Change 14.52% -12.88% -14.19%
% of Gross Profit
Depreciation & Amortization $175.0K $149.0K $128.0K
YoY Change 34.62% 13.74% 2.4%
% of Gross Profit
Operating Expenses $42.53M $45.36M $37.91M
YoY Change 28.34% 28.44% 12.87%
Operating Profit -$42.53M -$45.36M -$37.91M
YoY Change 28.34% 28.44% 12.87%
Interest Expense $9.277M $5.667M $2.759M
YoY Change 524.71% 351.19% 116.9%
% of Operating Profit
Other Income/Expense, Net -$8.562M -$5.557M -$2.759M
YoY Change 318.07% 350.69% 119.14%
Pretax Income -$51.09M -$50.92M -$40.67M
YoY Change 39.36% 39.31% 16.72%
Income Tax
% Of Pretax Income
Net Earnings -$51.09M -$50.92M -$40.67M
YoY Change 39.36% 39.31% 16.71%
Net Earnings / Revenue
Basic Earnings Per Share -$1.32 -$1.33 -$1.07
Diluted Earnings Per Share -$1.32 -$1.33 -$1.069M
COMMON SHARES
Basic Shares Outstanding 39.18M 38.27M 31.71M
Diluted Shares Outstanding 38.82M 38.27M 38.04M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $196.8M $207.4M $138.1M
YoY Change -12.37% -1.09% -41.98%
Cash & Equivalents $196.8M $207.4M $138.1M
Short-Term Investments
Other Short-Term Assets $975.0K $1.865M $7.651M
YoY Change 40.29% 11.74% 59.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $197.8M $209.3M $145.7M
YoY Change -12.21% -0.98% -39.97%
LONG-TERM ASSETS
Property, Plant & Equipment $831.0K $883.0K $708.0K
YoY Change 20.09% 9.96% -77.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $805.0K $805.0K $805.0K
YoY Change 136.07% 176.63% 101.25%
Total Long-Term Assets $4.118M $4.245M $3.308M
YoY Change 34.4% 30.98% -8.11%
TOTAL ASSETS
Total Short-Term Assets $197.8M $209.3M $145.7M
Total Long-Term Assets $4.118M $4.245M $3.308M
Total Assets $201.9M $213.5M $149.0M
YoY Change -11.58% -0.5% -39.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.135M $5.758M $2.858M
YoY Change 27.82% 6.61% -73.78%
Accrued Expenses $13.29M $13.78M $7.565M
YoY Change 20.37% 55.83% -58.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $945.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $22.88M $21.08M $11.39M
YoY Change -17.73% -46.8% -72.07%
LONG-TERM LIABILITIES
Long-Term Debt $93.88M $92.43M $91.04M
YoY Change 6.31% 147.54% 155.72%
Other Long-Term Liabilities $7.500M $7.500M $7.500M
YoY Change -14.58% 81.82% 33.93%
Total Long-Term Liabilities $101.4M $99.93M $98.54M
YoY Change 4.42% 141.0% 139.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.88M $21.08M $11.39M
Total Long-Term Liabilities $101.4M $99.93M $98.54M
Total Liabilities $228.4M $220.5M $111.0M
YoY Change 82.84% 167.43% 35.38%
SHAREHOLDERS EQUITY
Retained Earnings -$672.0M -$621.0M -$570.0M
YoY Change 36.17% 35.91%
Common Stock $645.6M $614.0M $608.1M
YoY Change 8.14% 4.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$26.42M -$7.000M $38.04M
YoY Change
Total Liabilities & Shareholders Equity $201.9M $213.5M $149.0M
YoY Change -11.58% -0.5% -39.51%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$51.09M -$50.92M -$40.67M
YoY Change 39.36% 39.31% 16.71%
Depreciation, Depletion And Amortization $175.0K $149.0K $128.0K
YoY Change 34.62% 13.74% 2.4%
Cash From Operating Activities -$35.02M -$25.72M -$45.10M
YoY Change 20.47% -9.32% -9.37%
INVESTING ACTIVITIES
Capital Expenditures -$134.0K -$428.0K $67.00K
YoY Change 857.14% 872.73% -60.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$134.0K -$428.0K -$67.00K
YoY Change 857.14% 872.73% -60.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.60M 95.45M 0.000
YoY Change -44.14% 89943.4% -100.0%
NET CHANGE
Cash From Operating Activities -35.02M -25.72M -45.10M
Cash From Investing Activities -134.0K -428.0K -67.00K
Cash From Financing Activities 24.60M 95.45M 0.000
Net Change In Cash -10.55M 69.30M -45.17M
YoY Change -170.6% -344.91% -8.79%
FREE CASH FLOW
Cash From Operating Activities -$35.02M -$25.72M -$45.10M
Capital Expenditures -$134.0K -$428.0K $67.00K
Free Cash Flow -$34.88M -$25.29M -$45.17M
YoY Change 20.07% -10.69% -9.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-10000
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
742-8466
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
PHAT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001783183
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39094
dei Entity Registrant Name
EntityRegistrantName
PHATHOM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4151574
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
-293000
phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
50000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
464000
CY2022Q2 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
2501000
CY2021Q4 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
2330000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-93000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
628000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21075000
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39175205
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
207392000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
183259000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1865000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18921000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3267000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
209257000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
92432000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
186526000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
89671000
CY2022Q2 phat Revenue Interest Financing Liability
RevenueInterestFinancingLiability
98103000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1392000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1183000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
883000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2557000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1914000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
805000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
341000
CY2022Q2 us-gaap Assets
Assets
213502000
CY2021Q4 us-gaap Assets
Assets
189431000
CY2022Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
69000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
1343000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5758000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
213502000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189431000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5150000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
CY2022Q2 phat Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
341000
CY2021Q4 phat Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
1402000
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
565000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
477000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13783000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11405000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7500000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7500000
CY2022Q2 us-gaap Liabilities
Liabilities
220502000
CY2021Q4 us-gaap Liabilities
Liabilities
117275000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39072046
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31656035
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38372403
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30511226
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
19
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
613952000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
601523000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-620955000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-529370000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-7000000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72156000
CY2022Q2 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
370000
CY2021Q2 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
905000
phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1800000
phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1846000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18815000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38272044
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38272044
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21597000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36475000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42178000
CY2022Q2 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
0
CY2021Q2 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
0
phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
0
phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
16000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26548000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13722000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46794000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26725000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
45363000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
35319000
us-gaap Operating Expenses
OperatingExpenses
83269000
us-gaap Operating Expenses
OperatingExpenses
68903000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45363000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35319000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83269000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68903000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
112000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Investment Income Interest
InvestmentIncomeInterest
119000
us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2022Q2 us-gaap Interest Expense
InterestExpense
5667000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1256000
us-gaap Interest Expense
InterestExpense
8426000
us-gaap Interest Expense
InterestExpense
2528000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5557000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1233000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8316000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2492000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50920000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36552000
us-gaap Net Income Loss
NetIncomeLoss
-91585000
us-gaap Net Income Loss
NetIncomeLoss
-71395000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5885000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50920000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12860000
phat Increase Decrease In Clinical Accrued Trial Expenses
IncreaseDecreaseInClinicalAccruedTrialExpenses
-1061000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36636164
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.76
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36636164
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38155151
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38155151
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36468498
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36468498
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72156000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
254000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5775000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
515000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-40665000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
38035000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-7000000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
194271000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
412000
CY2021Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
323000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3818000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
358000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-34843000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
164339000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4237000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-36552000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
132128000
us-gaap Profit Loss
ProfitLoss
-91585000
us-gaap Profit Loss
ProfitLoss
-71395000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
277000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
256000
us-gaap Share Based Compensation
ShareBasedCompensation
11660000
us-gaap Share Based Compensation
ShareBasedCompensation
8055000
us-gaap Paid In Kind Interest
PaidInKindInterest
1713000
phat Accrued Interest On Revenue Interest Financing Liability
AccruedInterestOnRevenueInterestFinancingLiability
2657000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1049000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
698000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-874000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-540000
phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
82000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1402000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2203000
phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
-1102000
phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
722000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2865000
phat Increase Decrease In Clinical Accrued Trial Expenses
IncreaseDecreaseInClinicalAccruedTrialExpenses
-5759000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
516000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24133000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
88000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-77827000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183259000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
883000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70818000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78129000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
495000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-495000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
516000
phat Net Proceeds From Revenue Interest Financing Transaction
NetProceedsFromRevenueInterestFinancingTransaction
95446000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95446000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
287496000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
207392000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
209669000
us-gaap Interest Paid Net
InterestPaidNet
2919000
us-gaap Interest Paid Net
InterestPaidNet
1833000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
phat Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
554000
phat Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock
NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
515000
phat Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock
NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock
358000
phat Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock
NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
254000
phat Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock
NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock
323000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development expenses and the valuation of various equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></p>
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1129000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
852000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q2 phat Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2021Q2 phat Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2022Q2 phat Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2021Q2 phat Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
phat Purchase Commitment Expense
PurchaseCommitmentExpense
0
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
445185
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2557000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1914000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2557000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2012000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1502000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
650000
CY2022Q2 us-gaap Depreciation
Depreciation
149000
CY2021Q2 us-gaap Depreciation
Depreciation
131000
us-gaap Depreciation
Depreciation
277000
us-gaap Depreciation
Depreciation
256000
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2021 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2022Q2 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
4314000
CY2021Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3165000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5201000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6344000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4229000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1855000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13783000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11405000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1914000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
628000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1392000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1183000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2020000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1670000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2022Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
7790000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
30139000
CY2022Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
105773000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
289000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
734000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
753000
CY2022Q2 phat Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
513000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2289000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
269000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2020000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
628000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1392000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M2D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0813
us-gaap Operating Lease Payments
OperatingLeasePayments
700000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2022Q2 phat Long Term Debt Noncurrent Excluding Unamortized Debt Discount
LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount
102703000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
10271000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
92432000
CY2022Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestRemainderOfFiscalYear
3638000
CY2022Q2 phat Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths
7510000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1144809
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
89548
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
32.99
CY2022Q2 phat Long Term Debt And Interest
LongTermDebtAndInterest
154850000
CY2022Q2 phat Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
54850000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000
phat Investors Right To Receive Royalties Termination Description
InvestorsRightToReceiveRoyaltiesTerminationDescription
The investors’ right to receive royalties on net sales will terminate when the investors have aggregate payments equal to 200% of the Investment Amount. In addition, at any time after the earlier of (i) April 30, 2024 and (ii) the date that the payment for erosive esophagitis regulatory approval is made, the Company has the right to make a cap payment equal to 200% of the Investment Amount less any royalties already paid, at which time the agreement will terminate.
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8829888
phat Investors Receipt Description
InvestorsReceiptDescription
If the investors have not received aggregate payments of at least 100% of the Investment Amount by December 31, 2028, and at least 200% of the Investment Amount by December 31, 2037, each a Minimum Amount, then the Company will be obligated to make a cash payment to the investors in an amount sufficient to gross the investors up to the applicable Minimum Amount.
phat Default Obligation Description
DefaultObligationDescription
Upon the occurrence of an event of default taking place prior to April 1, 2025, between April 1, 2025, and April 1, 2028, and after April 1, 2028, the Company is obligated to pay 1.30 times Investment Amount, 1.65 times Investment Amount, and 2.0 times investment amount, respectively, less any amounts the Company previously paid pursuant to the agreement.
phat Change In Control Description
ChangeInControlDescription
Upon the occurrence of a change in control event taking place prior to the earlier of April 1, 2024, or FDA approval of vonoprazan for erosive esophagitis, the Company is obligated to pay 200% of the Investment Amount plus either 15% of the Investment Amount if occurrence prior to May 3, 2023, or plus 30% of the Investment Amount if occurrence thereafter.
CY2022Q2 phat Gross Proceeds From Revenue Interest Financing Agreement
GrossProceedsFromRevenueInterestFinancingAgreement
100000000.0
CY2022Q2 phat Payment Of Transaction Costs
PaymentOfTransactionCosts
4600000
CY2022Q2 phat Net Proceeds From Revenue Interest Financing Transaction
NetProceedsFromRevenueInterestFinancingTransaction
95400000
CY2022Q2 phat Revenue Interest Financing Liability
RevenueInterestFinancingLiability
98100000
CY2022Q2 phat Gross Proceeds From Revenue Interest Financing Agreement
GrossProceedsFromRevenueInterestFinancingAgreement
100000000
CY2022Q2 phat Payment Of Transaction Costs
PaymentOfTransactionCosts
4554000
CY2022Q2 phat Interest Expense Related To Revenue Interest Financing Liability
InterestExpenseRelatedToRevenueInterestFinancingLiability
2657000
CY2022Q2 phat Revenue Interest Financing Liability
RevenueInterestFinancingLiability
98103000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
699624
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
CY2021Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2021Q3 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
18394
CY2022Q1 phat Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled
DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled
16756
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4186729
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M4D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13973000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1520297
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5617478
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M2D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1435000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2013657
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M25D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
838000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
47900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6604
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6738
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0189
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0064
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5885000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4237000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11660000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8055000

Files In Submission

Name View Source Status
0000950170-22-013743-index-headers.html Edgar Link pending
0000950170-22-013743-index.html Edgar Link pending
0000950170-22-013743.txt Edgar Link pending
0000950170-22-013743-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
phat-20220630.htm Edgar Link pending
phat-20220630.xsd Edgar Link pending
phat-20220630_cal.xml Edgar Link unprocessable
phat-20220630_def.xml Edgar Link unprocessable
phat-20220630_htm.xml Edgar Link completed
phat-20220630_lab.xml Edgar Link unprocessable
phat-20220630_pre.xml Edgar Link unprocessable
phat-ex10_2.htm Edgar Link pending
phat-ex10_3.htm Edgar Link pending
phat-ex10_4.htm Edgar Link pending
phat-ex10_5.htm Edgar Link pending
phat-ex10_6.htm Edgar Link pending
phat-ex31_1.htm Edgar Link pending
phat-ex31_2.htm Edgar Link pending
phat-ex32_1.htm Edgar Link pending
phat-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending